RCi188

General

Cell Line

hPSCreg name PFIZi009-A
Cite as:
PFIZi009-A (RRID:CVCL_RG04)
Alternative name(s)
RCi188
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
PFIZi018-A
(BC143c8, RCi207)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi015-A
(OD003-s5)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi016-A
(OD005-s9)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi017-A
(BC142c7, RCi209)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi019-A
(RCi202, BC145c6)
Donor's gene variants:
SCN1A, SCN1A
Donor diseases:
Dravet syndrome
PFIZi014-A
(OD002-s7)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
PFIZi021-A
(OD001-s7)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
UKBi010-A
(iLB-DS-95f-r8)
Donor's gene variants:
SCN1A
Donor diseases:
Dravet syndrome
INSRMi004-A
(PC118_c7)
Donor's gene variants:
SCN1A
Donor diseases:
epilepsy
KAIMRCi003-A
(DRVT-iPSC#1)
Donor's gene variants:
SCN9A, CPLX1
Donor diseases:
Dravet Syndrome
KAIMRCi003-B
(DRVT-iPSC#2)
Donor's gene variants:
SCN9A, CPLX1
Donor diseases:
Dravet Syndrome
IMBAi019-A
(623_DS22 #10)
Donor diseases:
Dravet Syndrome
IMBAi018-A
(622_DS04 #1)
Donor diseases:
Dravet Syndrome
IMBAi020-A
(624_DS40 #8)
Donor diseases:
Dravet Syndrome
Last update 10th March 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Pfizer Limited - Pfizer (PFIZ)
Distributors

External Databases

BioSamples SAMEA4085222
Cellosaurus CVCL_RG04
Wikidata Q54947261

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 25-29

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMEI
  • Severe myoclonus epilepsy of infancy
  • Severe myoclonic epilepsy of infancy
Genetic variants
SCN1A (target)
2q24.3
NM_006920.4:c.314C>T
Heterozygous
SCV000242702.10
Transition C > T, Nucleotide position 314, codon 105, Amino Acid Change Threonine > Isoleucine, Variant Type: heterozygous

External Databases (Donor)

BioSamples SAMEA4085220

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: Anjanette Burns / Dr Orrin Devinsky
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Dravet Syndrome / Epilepsy
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? NYU IRB
Approval number
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? NYU IRB
Approval number
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: Restricted to research into Dravet Syndrome / Epilepsy
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? Yes
Further constraints on use Restricted to research into Dravet Syndrome / Epilepsy
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
  • normoblast
Age of donor (at collection) 25-29

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
GATA6
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
VIM
Yes
NCAM1
Yes
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
NeuroD1
Yes
HES5
Yes
PAX6
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 16

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 17
Karyotyping method: G-Banding

Other Genotyping (Cell Line)